Altogether, these analyses support the notion of a molecular system whereby miR-29b inhibits aggressive GBM development via BCL2L2 inhibition, and implicate miR-29b as a potential candidate in anti-cancer therapy (Figure 7). Here, BCL2L2 is linked to glioblastoma.